GT201300253A - Preparacion de gadobutrol de alta pureza - Google Patents
Preparacion de gadobutrol de alta purezaInfo
- Publication number
- GT201300253A GT201300253A GT201300253A GT201300253A GT201300253A GT 201300253 A GT201300253 A GT 201300253A GT 201300253 A GT201300253 A GT 201300253A GT 201300253 A GT201300253 A GT 201300253A GT 201300253 A GT201300253 A GT 201300253A
- Authority
- GT
- Guatemala
- Prior art keywords
- preparation
- high purity
- purity gadobutrol
- gadobutrol
- purity
- Prior art date
Links
- ZPDFIIGFYAHNSK-CTHHTMFSSA-K 2-[4,10-bis(carboxylatomethyl)-7-[(2r,3s)-1,3,4-trihydroxybutan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;gadolinium(3+) Chemical compound [Gd+3].OC[C@@H](O)[C@@H](CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-CTHHTMFSSA-K 0.000 title abstract 2
- 229960003411 gadobutrol Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LO QUE SE DESCRIBE ES UN PROCESO PARA LA PRODUCCIÓN DE GADOBUTROL DE ALTA PUREZA CON UNA PUREZA (SEGÚN HPLC) DE MÁS DE 99.7OR 99,8 O 99,9% Y EL USO PARA LA PREPARACIÓN DE UNA FORMULACIÓN FARMACÉUTICA PARA LA ADMINISTRACIÓN PARENTERAL. EL PROCESO SE LLEVA A CABO UTILIZANDO CONDICIONES DE CRISTALIZACIÓN CONTROLADA ESPECÍFICAMENTE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102011100128 | 2011-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201300253A true GT201300253A (es) | 2015-01-16 |
Family
ID=46208435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201300253A GT201300253A (es) | 2011-04-21 | 2013-10-18 | Preparacion de gadobutrol de alta pureza |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10072027B2 (es) |
| EP (2) | EP2896405B1 (es) |
| JP (3) | JP6096757B2 (es) |
| KR (3) | KR102003570B1 (es) |
| CN (1) | CN103547573B (es) |
| AR (1) | AR086190A1 (es) |
| AU (2) | AU2012244791B2 (es) |
| BR (1) | BR112013027028B1 (es) |
| CA (1) | CA2833659C (es) |
| CL (1) | CL2013003045A1 (es) |
| CO (1) | CO6801752A2 (es) |
| CU (2) | CU24439B1 (es) |
| DK (1) | DK2896405T3 (es) |
| DO (1) | DOP2013000245A (es) |
| EA (2) | EA201600272A1 (es) |
| EC (1) | ECSP13013010A (es) |
| ES (1) | ES2780599T3 (es) |
| GT (1) | GT201300253A (es) |
| HR (1) | HRP20200336T1 (es) |
| IL (1) | IL228885A (es) |
| LT (1) | LT2896405T (es) |
| MX (1) | MX362133B (es) |
| MY (1) | MY163709A (es) |
| NZ (1) | NZ616637A (es) |
| PE (1) | PE20141325A1 (es) |
| PH (1) | PH12013502168B1 (es) |
| PL (1) | PL2896405T3 (es) |
| PT (1) | PT2896405T (es) |
| RS (1) | RS60001B1 (es) |
| SG (1) | SG194511A1 (es) |
| SI (1) | SI2896405T1 (es) |
| TW (1) | TW201249818A (es) |
| WO (1) | WO2012143355A1 (es) |
| ZA (1) | ZA201308706B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012143355A1 (en) * | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Preparation of high-purity gadobutrol |
| WO2015117911A1 (en) * | 2014-02-06 | 2015-08-13 | Agfa Healthcare | Process for purifying 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid |
| KR101693400B1 (ko) * | 2014-09-17 | 2017-01-05 | 에스티팜 주식회사 | 칼코부트롤의 제조방법 |
| KR101646211B1 (ko) * | 2014-11-12 | 2016-08-05 | (주)디아이테크 | 자기공명영상용 조영제의 제조방법 |
| KR101653064B1 (ko) * | 2014-12-26 | 2016-09-09 | 에스티팜 주식회사 | 가도부트롤의 제조방법 |
| EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
| AU2017333698B2 (en) | 2016-09-27 | 2020-12-24 | Bayer Pharma Aktiengesellschaft | Method for producing the crystalline form of modification a of calcobutrol |
| CN106543094A (zh) * | 2016-11-04 | 2017-03-29 | 嘉实（湖南）医药科技有限公司 | 高纯度钆布醇的制备方法 |
| WO2018096082A1 (en) | 2016-11-28 | 2018-05-31 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
| GB201703227D0 (en) * | 2017-01-20 | 2017-04-12 | Ge Healthcare As | Plastic containers |
| CN109293592A (zh) * | 2017-07-24 | 2019-02-01 | 天津科伦药物研究有限公司 | 一种制备钆布醇的方法 |
| KR101971435B1 (ko) * | 2017-08-29 | 2019-04-24 | 주식회사 엔지켐생명과학 | 가도부트롤 중간체 및 이를 이용한 가도부트롤의 제조 방법 |
| CN108840832A (zh) * | 2018-06-29 | 2018-11-20 | 广州康瑞泰药业有限公司 | 一种钆布醇中间体的制备方法 |
| US12227527B2 (en) | 2018-07-10 | 2025-02-18 | Biophore India Pharmaceuticals Pvt. Ltd | Process for the preparation of 2,2′,2″-(10-((2R,3S)-1,3,4-trihydroxy butan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid and its complexes |
| KR102167614B1 (ko) * | 2018-08-23 | 2020-10-19 | 에스티팜 주식회사 | 가도부트롤의 제조방법 |
| PE20211471A1 (es) * | 2018-11-23 | 2021-08-05 | Bayer Ag | Formulacion de medios de contraste y proceso para prepararlos |
| WO2020122998A1 (en) | 2018-12-12 | 2020-06-18 | Medibeacon Inc. | Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy |
| GB201919073D0 (en) * | 2019-12-20 | 2020-02-05 | Ge Healthcare As | Novel manufacturing process |
| CN113087680A (zh) * | 2020-01-08 | 2021-07-09 | 威智医药有限公司 | Dota晶型及其制备方法 |
| CN113105407A (zh) * | 2020-01-13 | 2021-07-13 | 北京北陆药业股份有限公司 | 一种钆布醇新型晶型及其制备方法 |
| KR20210114742A (ko) * | 2020-03-11 | 2021-09-24 | 주식회사 엔지켐생명과학 | 칼테리돌의 제조방법 |
| CN114539178B (zh) * | 2020-11-26 | 2024-03-15 | 江苏恒瑞医药股份有限公司 | 一种钆布醇的纯化方法 |
| CN114573522A (zh) * | 2020-11-30 | 2022-06-03 | 江苏恒瑞医药股份有限公司 | 一种考布曲钙的新晶型及其制备方法 |
| US20220242885A1 (en) * | 2021-02-01 | 2022-08-04 | Inventure, LLC | Synthesis methods and compositions of low intermediate and low dichelate intermediate contrast agents |
| CN112939806B (zh) * | 2021-03-08 | 2023-05-16 | 山东新华制药股份有限公司 | 一种卡比多巴的精制方法 |
| CN113527223B (zh) * | 2021-06-22 | 2023-05-09 | 安徽普利药业有限公司 | 一种钆布醇的精制方法 |
| CN114105897B (zh) * | 2021-07-29 | 2023-04-04 | 安徽普利药业有限公司 | 一种钆特醇的制备方法 |
| CN116023345A (zh) * | 2023-02-16 | 2023-04-28 | 渭南瑞联制药有限责任公司 | 一种钆布醇中间体杂质的制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| NL194579C (nl) | 1983-01-21 | 2002-08-05 | Schering Ag | Diagnostisch middel. |
| US4885363A (en) | 1987-04-24 | 1989-12-05 | E. R. Squibb & Sons, Inc. | 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
| DE3625417C2 (de) | 1986-07-28 | 1998-10-08 | Schering Ag | Tetraazacyclododecan-Derivate |
| DE3640708C2 (de) | 1986-11-28 | 1995-05-18 | Schering Ag | Verbesserte metallhaltige Pharmazeutika |
| DE4009119A1 (de) | 1990-03-19 | 1991-09-26 | Schering Ag | 1,4,7,10-tetraazacyclododecan-butyltriole, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| US7385041B2 (en) | 1990-04-25 | 2008-06-10 | Bracco International B.V. | Dual functioning excipient for metal chelate contrast agents |
| DE4035760A1 (de) | 1990-11-08 | 1992-05-14 | Schering Ag | Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel |
| DE4237943C2 (de) | 1992-11-06 | 1997-10-23 | Schering Ag | Verfahren zur Herstellung von Metallkomplexen der N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,7,10-tetraazacyclododecan- und N-beta-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivate |
| DE4140779A1 (de) | 1991-12-06 | 1993-06-09 | Schering Ag Berlin Und Bergkamen, 1000 Berlin, De | Verfahren zur herstellung von mono-n-substituierten tetraazamakrocyclen |
| US5410043A (en) | 1991-12-06 | 1995-04-25 | Schering Aktiengesellschaft | Process for the production of mono-N-substituted tetraaza macrocycles |
| DE4218744C2 (de) * | 1992-06-04 | 1997-11-06 | Schering Ag | Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe |
| IT1275426B (it) | 1995-05-16 | 1997-08-07 | Bracco Spa | Recupero del gadolinio e dei suoi agenti complessanti da soluzioni acquose contenenti i loro complessi |
| US5744616A (en) | 1996-02-26 | 1998-04-28 | Schering Aktiengesellschaft | Process for the production of 1,4,7,10-tetraazacyclododecane and its derivatives |
| DE19608307C1 (de) | 1996-02-26 | 1997-08-28 | Schering Ag | Verfahren zur Herstellung von 1,4,7,10-Tetraazacyclododecan und dessen Derivaten |
| DE19724186C2 (de) * | 1997-06-02 | 2002-07-18 | Schering Ag | Verfahren zur Mono- und 1,7-Bis-N-ß-Hydroxyalkylierung von Cyclen und die entsprechenden N-ß-Hydroxyalkyl-1,4,7,10-tetraazacyclododecan-Li-Salz-Komplexe |
| IT1292127B1 (it) | 1997-06-11 | 1999-01-25 | Bracco Spa | Processo per la dissalazione di sostanze instabili a ph acidi |
| IT1292128B1 (it) * | 1997-06-11 | 1999-01-25 | Bracco Spa | Processo per la preparazione di chelanti macrociclici e loro chelati con ioni metallici paramagnetici |
| EP0985548B1 (fr) | 1998-09-08 | 2002-10-23 | Kba-Giori S.A. | Machine d'impression de sécurité sur des papiers-valeur |
| DE10064467C2 (de) | 2000-12-15 | 2002-10-31 | Schering Ag | Lithium-Komplexe von N-(1-Hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecan, deren Herstellung und Verwendung |
| DE102009053171B4 (de) | 2009-11-04 | 2011-07-21 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol) |
| WO2011054480A1 (de) | 2009-11-09 | 2011-05-12 | Bayer Schering Pharma Aktiengesellschaft | Gadobutrolherstellung mittels keramischer membran |
| DE102010013833A1 (de) | 2010-03-29 | 2011-09-29 | Bayer Schering Pharma Aktiengesellschaft | Herstellung von Gadobutrol mittels Dimethylformamiddimethylacetal |
| DE102010023105A1 (de) | 2010-06-04 | 2011-12-08 | Bayer Schering Pharma Aktiengesellschaft | Gadobutrolherstellung im Eintopfverfahren mittels DMF-acetal und N-Methylimidazol |
| WO2012143355A1 (en) * | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Preparation of high-purity gadobutrol |
| KR101653064B1 (ko) | 2014-12-26 | 2016-09-09 | 에스티팜 주식회사 | 가도부트롤의 제조방법 |
-
2012
- 2012-04-17 WO PCT/EP2012/057013 patent/WO2012143355A1/en not_active Ceased
- 2012-04-17 KR KR1020137030655A patent/KR102003570B1/ko active Active
- 2012-04-17 LT LTEP14172784.2T patent/LT2896405T/lt unknown
- 2012-04-17 DK DK14172784.2T patent/DK2896405T3/da active
- 2012-04-17 PE PE2013002379A patent/PE20141325A1/es active IP Right Grant
- 2012-04-17 CN CN201280024781.7A patent/CN103547573B/zh active Active
- 2012-04-17 KR KR1020197017528A patent/KR20190079682A/ko not_active Ceased
- 2012-04-17 EP EP14172784.2A patent/EP2896405B1/en active Active
- 2012-04-17 CA CA2833659A patent/CA2833659C/en active Active
- 2012-04-17 EA EA201600272A patent/EA201600272A1/ru unknown
- 2012-04-17 SG SG2013077094A patent/SG194511A1/en unknown
- 2012-04-17 SI SI201231741T patent/SI2896405T1/sl unknown
- 2012-04-17 ES ES14172784T patent/ES2780599T3/es active Active
- 2012-04-17 AU AU2012244791A patent/AU2012244791B2/en active Active
- 2012-04-17 CU CU2016000163A patent/CU24439B1/es unknown
- 2012-04-17 MX MX2013012290A patent/MX362133B/es active IP Right Grant
- 2012-04-17 RS RS20200238A patent/RS60001B1/sr unknown
- 2012-04-17 MY MYPI2013701962A patent/MY163709A/en unknown
- 2012-04-17 KR KR1020207014352A patent/KR20200059319A/ko not_active Ceased
- 2012-04-17 PT PT141727842T patent/PT2896405T/pt unknown
- 2012-04-17 BR BR112013027028-4A patent/BR112013027028B1/pt active IP Right Grant
- 2012-04-17 NZ NZ616637A patent/NZ616637A/en unknown
- 2012-04-17 EP EP12725635.2A patent/EP2699556A1/en not_active Ceased
- 2012-04-17 EA EA201301182A patent/EA026572B1/ru not_active IP Right Cessation
- 2012-04-17 PH PH1/2013/502168A patent/PH12013502168B1/en unknown
- 2012-04-17 US US14/112,994 patent/US10072027B2/en active Active
- 2012-04-17 PL PL14172784T patent/PL2896405T3/pl unknown
- 2012-04-17 JP JP2014505591A patent/JP6096757B2/ja active Active
- 2012-04-20 AR ARP120101354A patent/AR086190A1/es active IP Right Grant
- 2012-04-23 TW TW101114466A patent/TW201249818A/zh unknown
-
2013
- 2013-10-15 IL IL228885A patent/IL228885A/en active IP Right Grant
- 2013-10-18 GT GT201300253A patent/GT201300253A/es unknown
- 2013-10-21 CO CO13248770A patent/CO6801752A2/es not_active Application Discontinuation
- 2013-10-21 CL CL2013003045A patent/CL2013003045A1/es unknown
- 2013-10-21 CU CU2013000142A patent/CU20130142A7/es unknown
- 2013-10-21 DO DO2013000245A patent/DOP2013000245A/es unknown
- 2013-11-05 EC ECSP13013010 patent/ECSP13013010A/es unknown
- 2013-11-20 ZA ZA2013/08706A patent/ZA201308706B/en unknown
-
2016
- 2016-11-08 JP JP2016217880A patent/JP2017031220A/ja active Pending
-
2017
- 2017-06-30 AU AU2017204495A patent/AU2017204495A1/en not_active Abandoned
- 2017-07-31 US US15/664,060 patent/US10435417B2/en active Active
-
2018
- 2018-09-05 JP JP2018165787A patent/JP2018188477A/ja active Pending
-
2020
- 2020-02-27 HR HRP20200336TT patent/HRP20200336T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201300253A (es) | Preparacion de gadobutrol de alta pureza | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| DOP2021000179A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| ECSP14026138A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| PH12014500813A1 (en) | Novel [1,2,3] triazolo [4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor | |
| UA105042C2 (uk) | Самомікроемульговувана оральна фармацевтична композиція гідрофільного лікарського засобу і спосіб її одержання | |
| MX2020008468A (es) | Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas. | |
| GT201200250A (es) | Ariltriazolonas ligadas a bisarilo y su uso | |
| MY183312A (en) | Pharmaceutical formulation | |
| ECSP13012668A (es) | Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso | |
| MY168212A (en) | A new therapeutical composition containing apomorphine as active ingredient | |
| BR112013004662B8 (pt) | Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica | |
| PH12014501026A1 (en) | [1, 2, 3]triazolo[4,5-d] pyrimidine derivatives as agonists of the cannabinoid receptor 2 agonists | |
| CU20120137A7 (es) | Hidrato del hidrocloruro de agomelatina y preparación de éste | |
| WO2014036502A3 (en) | Tetracycline compounds | |
| BR112012017845A2 (pt) | novo processo para produção de derivados de benzofenona | |
| MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
| CL2012003497A1 (es) | Procedimiento para preparar el compuesto diácido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico cristalino; su uso para preparar una formulación galénica del complejo de gadolinio de diacido 3,6,9-triaza-3,6,9-tris(carboximetil)-4-(4-etoxibencil)-undecanoico; y el compuesto con una pureza superior al 99%. | |
| BR112015022859A2 (pt) | processo para fabricação de mono-hidrato trissódico gadofosveset | |
| UA113058C2 (xx) | Кристалічна форма vii агомелатину, спосіб її приготування і застосування і фармацевтична композиція, яка її містить | |
| WO2015063795A3 (en) | Novel process for preparation of optically pure norephedrine and its derivatives | |
| HK1212978A1 (zh) | 芥子酸的新型衍生物 | |
| DOP2015000062A (es) | Derivados de macrólidos, su preparación y su uso terapéutico | |
| WO2015087343A3 (en) | An improved process for the preparation of nilotinib and pharmaceutically acceptable salts thereof |